<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACC Basic Transl Sci</journal-id><journal-id journal-id-type="iso-abbrev">JACC Basic Transl Sci</journal-id><journal-title-group><journal-title>JACC: Basic to Translational Science</journal-title></journal-title-group><issn pub-type="epub">2452-302X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9436824</article-id><article-id pub-id-type="pii">S2452-302X(22)00122-X</article-id><article-id pub-id-type="doi">10.1016/j.jacbts.2022.03.007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research - Preclinical</subject></subj-group></article-categories><title-group><article-title>Parkin Insufficiency Accentuates High-Fat&#x000a0;Diet&#x02013;Induced Cardiac Remodeling and Contractile Dysfunction Through VDAC1-Mediated Mitochondrial Ca<sup>2+</sup>&#x000a0;Overload</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Wu</surname><given-names>Ne N.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Bi</surname><given-names>Yaguang</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Ajoolabady</surname><given-names>Amir</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#x02217;</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>You</surname><given-names>Fei</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Sowers</surname><given-names>James</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Wang</surname><given-names>Qiurong</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Ceylan</surname><given-names>Asli F.</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Zhang</surname><given-names>Yingmei</given-names></name><degrees>MD, PhD</degrees><email>zhangym197951@126.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Ren</surname><given-names>Jun</given-names></name><degrees>MD, PhD</degrees><email>jren_aldh2@outlook.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China</aff><aff id="aff2"><label>b</label>Department of Cardiology, Xi&#x02019;an Central Hospital, Xi&#x02019;an, China</aff><aff id="aff3"><label>c</label>Diabetes and Cardiovascular Research Center, University of Missouri Columbia, Columbia, Missouri, USA</aff><aff id="aff4"><label>d</label>Faculty of Medicine, Department of Medical Pharmacology, Ankara Yildirim Beyazit University, Bilkent, Ankara, Turkey</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Address for correspondence:</bold> Dr Jun Ren, Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China. <email>jren_aldh2@outlook.com</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Dr Yingmei Zhang, Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China. <email>zhangym197951@126.com</email></corresp><fn id="fn1"><label>&#x02217;</label><p id="ntpara0010">Drs Wu, Bi, and Ajoolabady contributed equally to this work and are joint first authors.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>8</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2022</year></pub-date><volume>7</volume><issue>8</issue><fpage>779</fpage><lpage>796</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2021</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2022</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d35e12" ext-link-type="doi" xlink:href="10.1016/j.jacbts.2022.04.008"/><abstract abstract-type="graphical" id="abs0015"><title>Visual Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>HIGHLIGHTS</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Mitochondrial Ca<sup>2+</sup> overload contributes to obesity-induced cardiac injury.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Parkin deletion aggravates obesity cardiomyopathy independent of systemic effects.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Parkin regulates VDAC1 degradation, but not other mitochondrial Ca<sup>2+</sup> transporters.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Parkin expression or VDAC1 inhibition rescues cardiomyocyte contractile defect.</p></list-item></list></p></abstract><abstract id="abs0010"><p>Mitochondrial Ca<sup>2+</sup> overload contributes to obesity cardiomyopathy, yet mechanisms that directly regulate it remain elusive. The authors investigated the role of Parkin on obesity-induced cardiac remodeling and dysfunction in human hearts and a mouse model of 24-week high-fat diet (HFD) feeding. Parkin knockout aggravated HFD-induced cardiac remodeling and dysfunction, mitochondrial Ca<sup>2+</sup> overload, and apoptosis without affecting global metabolism, blood pressure, and aortic stiffness. Parkin deficiency unmasked HFD-induced decline in voltage-dependent anion channel (VDAC) type 1 degradation through the ubiquitin-proteasome system but not other VDAC isoforms or mitochondrial Ca<sup>2+</sup> uniporter complex. These data suggest that Parkin-mediated proteolysis of VDAC type 1 is a promising therapeutic target for obesity cardiomyopathy.</p></abstract><kwd-group id="kwrds0010"><title>Key Words</title><kwd>Ca<sup>2+</sup> overload</kwd><kwd>heart</kwd><kwd>high-fat diet</kwd><kwd>mitochondria</kwd><kwd>Parkin</kwd><kwd>VDAC1</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations and Acronyms</title><kwd>AMCM, adult murine cardiomyocyte</kwd><kwd>BP, blood pressure</kwd><kwd>HFD, high-fat diet</kwd><kwd>LFD, low-fat diet</kwd><kwd>LV, left ventricular</kwd><kwd>MCU, mitochondrial Ca<sup>2+</sup> uniporter</kwd><kwd>mPTP, mitochondrial permeability transition pore</kwd><kwd>PA, palmitic acid</kwd><kwd>ROS, reactive oxygen species</kwd><kwd>TR<sub>90</sub>, time to 90% relengthening</kwd><kwd>VDAC, voltage-dependent anion channel</kwd><kwd>WT, wild-type</kwd></kwd-group></article-meta></front><body><p id="p0030">Obesity is reaching epidemic proportions globally, severely affecting quality of life and health care, triggering dyslipidemia, insulin resistance, diabetes mellitus, hypertension, and sleep apnea.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Uncorrected obesity prompts unfavorable changes in cardiac structure and function, including left ventricular (LV) hypertrophy, interstitial fibrosis, hemodynamic alterations, and diastolic dysfunction, a pathologic condition termed obesity cardiomyopathy.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> The pathogenesis of obesity cardiomyopathy remains elusive, making it challenging to engage effective measures besides weight reduction to halt progressive cardiac remodeling and dysfunction. Recent evidence has demonstrated an essential role for disturbance in mitochondrial Ca<sup>2+</sup> handling, especially Ca<sup>2+</sup> overload, in deranged redox balance, energy metabolism, cell survival, and cardiac function in the context of obesity.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Robust mitochondrial Ca<sup>2+</sup> influx is evident in the heart through physical contact sites between outer mitochondrial membrane and sarcoplasmic reticulum, namely, mitochondrial-associated membranes where voltage-dependent anion channels (VDACs) connect with sarcoplasmic reticulum Ca<sup>2+</sup> channels to ease rapid Ca<sup>2+</sup> transport from sarcoplasmic reticulum into mitochondria.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> VDAC1-mediated mitochondrial Ca<sup>2+</sup> import may also present at mitochondria-lysosome contact sites.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Ca<sup>2+</sup> enters the mitochondrial matrix via mitochondrial Ca<sup>2+</sup> uniporter (MCU) located within the inner mitochondrial membrane.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Both VDAC1 and the&#x000a0;MCU complex are deemed vital for mitochondrial Ca<sup>2+</sup> overload and oxidative stress&#x02013;induced apoptosis.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></p><p id="p0035">Recent evidence has depicted a major role for mitophagy (ie, engulfment of long-lived or damaged mitochondria in the double-membraned autophagosomes) in the maintenance of mitochondrial integrity and function, including mitochondrial Ca<sup>2+</sup> import, under pathologic stresses.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Parkin, an E3 ubiquitin ligase recruited to depolarized mitochondria to ubiquitinate outer mitochondrial membrane proteins, helps remove impaired mitochondria through the mitophagy machinery and promotes the proteasome-dependent degradation of mitochondrial proteins.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Nonetheless, changes of mitophagy in advanced stages of obesity and how Parkin regulates mitochondrial Ca<sup>2+</sup> import proteins remain at large. Given the pivotal role of Parkin in mitochondrial integrity, mitochondrial Ca<sup>2+</sup> load and cardiomyocyte survival,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> this study was designed to evaluate the effect of Parkin ablation on global metabolism, cardiac remodeling, and contractile and aortic function in high-fat diet (HFD)&#x02013;induced obesity and possible mechanisms involved. Results from our study reveal that Parkin deficiency accentuates cardiac remodeling, contractile (systolic and diastolic) dysfunction, mitochondrial impairment, and mitochondria-mediated cell death through mitochondrial Ca<sup>2+</sup> overload without affecting global metabolic dysfunction, aortic stiffness, and elevated blood pressure (BP) in diet-induced obesity, denoting a vital role for Parkin in the regulation of mitochondrial Ca<sup>2+</sup> influx.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Bioinformatics analysis</title><p id="p0040">Messenger RNA profiles of human hearts (specifically atrial biopsies) were downloaded from the Gene Expression Omnibus database (GSE159612), including 9 lean (body mass index 22.2 &#x000b1; 0.6&#x000a0;kg/m<sup>2</sup>) and 9 obese (body mass index 33.7 &#x000b1; 1.1&#x000a0;kg/m<sup>2</sup>) patients (information presented in <xref rid="mmc1" ref-type="supplementary-material">Supplemental Table&#x000a0;S1</xref>). Gene Ontology analysis and&#x000a0;gene set enrichment analysis were performed in R version 4.1.1 (see the <xref rid="mmc1" ref-type="supplementary-material">Supplemental Methods</xref> for details).</p></sec><sec id="sec1.2"><title>Human samples</title><p id="p0045">LV samples were obtained from unsuccessful cardiac transplants from 8 lean (body mass index 19.6 &#x000b1; 1.2&#x000a0;kg/m<sup>2</sup>) and 8 obese (body mass index 31.8 &#x000b1; 1.2&#x000a0;kg/m<sup>2</sup>; <italic>P&#x000a0;&#x0003c;</italic> 0.05 vs lean group) donors (<xref rid="mmc1" ref-type="supplementary-material">Supplemental Table&#x000a0;S2</xref>). The protocol was approved by the Sun Yat-Sen Memorial Hospital Ethics Committee (SYSEC-KY-KS-2019-019) and was in line with the principles defined in the Declaration of Helsinki.</p></sec><sec id="sec1.3"><title>Experimental animals and HFD feeding</title><p id="p0050">The experimental procedures described here were approved by the Institutional Animal Use and Care Committees of Zhongshan Hospital Fudan University and were in accordance with National Institutes of Health guidelines. In brief, wild-type (WT) and global Parkin knockout (Parkin<sup>&#x02212;/&#x02212;</sup>) mice (B6.129S4-Parktm1Shn/J, strain 006582) on C57BL/6J background were purchased from the Jackson Laboratory (see the <xref rid="mmc1" ref-type="supplementary-material">Supplemental Methods</xref> for details). Two-month-old male WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice were randomly assigned to a low-fat diet (LFD; 10% of calories from fat; D12450H, Research Diets) or an HFD (45% of total calories from fat; D12451, Research Diets) for 24&#x000a0;weeks.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Mice were anesthetized using ketamine (80&#x000a0;mg/kg; Pfizer) and xylazine (12&#x000a0;mg/kg; Bayer) before being sacrificed using cervical dislocation.</p></sec><sec id="sec1.4"><title>Metabolic cage</title><p id="p0055">Mice were individually housed and monitored in a semisealed metabolic monitoring system (CLAMS, Columbus Instruments) at 22&#x000b0;C with free access to food and water for 24 hours (7 <sc>AM</sc> to 7 <sc>AM</sc> the next day). Parameters of O<sub>2</sub> consumption, CO<sub>2</sub> production, respiratory exchange ratio (CO<sub>2</sub> production/O<sub>2</sub> consumption), heat production ([(3.815&#x000a0;+ 1.232&#x000a0;&#x000d7; respiratory exchange ratio)&#x000a0;&#x000d7; O<sub>2</sub> consumption]&#x000a0;&#x000d7; 1,000), and voluntary activity were determined for a 24-hour period.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p></sec><sec id="sec1.5"><title>Plasma file</title><p id="p0060">Blood glucose and plasma insulin levels were measured using a glucometer (Bayer) and enzyme-linked immunosorbent assay commercial kits (R &#x00026; D Systems). Homeostasis model assessment&#x02013;estimated insulin resistance index was calculated as: [fasting insulin (mU/L)&#x000a0;&#x000d7; fasting glucose (mmol/L)]/22.5.</p></sec><sec id="sec1.6"><title>Histologic examination:</title><p id="p0065">Following anesthesia, mice were sacrificed and hearts were excised and immediately placed in 10% neutral-buffered formalin at room temperature for 24 hours. Specimens were embedded in paraffin, cut into 5-&#x003bc;m sections, and stained with fluorescein isothiocyanate&#x02013;conjugated wheat germ agglutinin. Oil red O and Masson&#x02019;s trichrome staining was used to detect lipid and fibrosis, respectively. Images were captured using an Olympus BX-51 microscope (Olympus America) and analyzed using the Image J Fiji version 2.3.0 (National Institutes of Health).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p></sec><sec id="sec1.7"><title>Cardiac and vascular function assessment</title><p id="p0070">Mice were anesthetized prior to evaluation of cardiac and aortic function using 2-dimensionally guided M-mode and color Doppler echocardiography (Vevo 2100, FUJIFILM VisualSonics) equipped with a 22- to 55-MHz linear transducer (MS550D, FUJIFILM VisualSonics). Ejection fraction and heart rate were derived using Vevo 2100 echocardiography.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> LV diastolic function was assessed using the ratio of early to late ventricular filling velocities (E/A) and deceleration time. Systolic and diastolic BP were measured using a CODA semiautomated noninvasive device (Kent Scientific). The distance between the aortic arch and the bifurcation of left common carotid artery divided by pressure-wave transit time was used to generate pulse-wave velocity (see <xref rid="mmc1" ref-type="supplementary-material">Supplemental Methods</xref> for details).<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref></p></sec><sec id="sec1.8"><title>Isolation and treatment of mouse cardiomyocytes</title><p id="p0075">Adult murine cardiomyocytes (AMCMs) were collected from diet-fed male WT or Parkin<sup>&#x02212;/&#x02212;</sup> mice to examine contractile function and Ca<sup>2+</sup> levels.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> In addition, a cohort of AMCMs were treated with the proteasomal inhibitor MG132 and autophagy inhibitors (3-methyladenine and bafilomycin A1) to discern degradation modalities. AMCMs were also treated with palmitic acid (PA) in the absence or presence of the VDAC1 inhibitor or the mitochondrial permeability transition pore (mPTP)&#x02013;opening inducer. Neonatal mouse cardiomyocytes were isolated from 1-day-old WT male mice using a series of enzymatic digestions (Worthington Biochemical)<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> and were transduced with adenoviruses or small interfering RNA for mitophagy detection (see <xref rid="mmc1" ref-type="supplementary-material">Supplemental Methods</xref> for details).</p></sec><sec id="sec1.9"><title>Cell shortening and relengthening</title><p id="p0080">Mechanical properties of AMCMs were assessed using an IonOptix soft-edge system. Cardiomyocytes were field-stimulated at 0.5&#x000a0;Hz. Cell shortening and relengthening were assessed including peak shortening, time to peak shortening, time to 90% relengthening (TR<sub>90</sub>), and maximal velocities of shortening and relengthening (&#x000b1;dL/dt).<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p></sec><sec id="sec1.10"><title>Measurement of intracellular and mitochondrial Ca<sup>2+</sup></title><p id="p0085">AMCMs were loaded with Fura-2/AM (0.5&#x000a0;&#x003bc;M; F1201, Thermo Fisher Scientific) for 15&#x000a0;minutes, and fluorescence intensity was recorded with a dual-excitation fluorescence photomultiplier system (IonOptix). Qualitative change in Fura-2 fluorescence intensity was inferred from the Fura-2 fluorescence intensity ratio at the 2 wavelengths (360 and 380&#x000a0;nm). Fluorescence decay time (single exponential) was calculated as an indicator of intracellular Ca<sup>2+</sup> clearance.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Mitochondrial Ca<sup>2+</sup> transients were monitored using Rhod-2 <sc>AM</sc> (1&#x000a0;&#x003bc;M, 1 hour at 37&#x000b0;C; R1245MP, Thermo Fisher Scientific), followed by de-esterification for another hour in Rhod-2-free medium. Cells were exposed to light emitted by a 75-W lamp while being stimulated to contract at a frequency of 0.5&#x000a0;Hz. Mitochondrial Ca<sup>2+</sup> transients were presented as background-subtracted normalized fluorescence. In addition, a cohort of AMCMs were imaged through a confocal microscope (TCS SP8, Leica) with fluorescence excitation and emission maxima at 552 and 581&#x000a0;nm.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> The fluorescence intensity of Rhod-2 was analyzed using Image J Fiji version 2.3.0.</p></sec><sec id="sec1.11"><title>Transmission electron microscopy</title><p id="p0090">Small cubic pieces&#x000a0;&#x02264;1&#x000a0;mm<sup>3</sup> were dissected from left ventricles and were fixed with 2.5% glutaraldehyde in 0.1&#x000a0;M sodium phosphate (pH 7.4) overnight at 4&#x000b0;C. Following postfixation in 1% OsO<sub>4</sub>, samples were dehydrated through graded alcohols and were embedded in Epon Araldite. Ultrathin sections (50&#x000a0;nm) were cut using an ultramicrotome (UltraCut E, Leica) and stained with uranyl acetate and lead citrate. Images were captured using the FEI Tecnai G2 Spirit transmission electron microscope.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p></sec><sec id="sec1.12"><title>Reactive oxygen species detection</title><p id="p0095">Superoxide anion (O<sub>2</sub><sup>&#x02212;</sup>) was detected in heart sections (30&#x000a0;&#x003bc;m thick) using dihydroethidium staining (2&#x000a0;&#x003bc;M; Invitrogen) for 30&#x000a0;minutes in a humidified chamber at 37&#x000b0;C. Images were obtained using a computer-assisted microscope. For the detection of reactive oxygen species (ROS), isolated AMCMs were incubated with MitoSOX red mitochondrial superoxide indicator (5&#x000a0;&#x003bc;M; M36008, Thermo Fisher Scientific) for 30&#x000a0;minutes and were imaged using confocal microscopy.</p></sec><sec id="sec1.13"><title>Detection of mitophagy, mitochondrial function, and apoptosis</title><p id="p0100">Neonatal mouse cardiomyocytes were transfected with adenoviruses encoding mt-Keima (multiplicity of infection&#x000a0;=&#x000a0;50; Hanbio Biotechnology). Levels of mitophagy were quantified as the ratio of fluorescence signal area at 561-nm excitation to signal derived from 458-nm excitation with a 570- to 695-nm emission range using confocal microscopy.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Details of additional methods and materials, including mitochondrial aconitase activity, NAD<sup>+</sup> levels, and western blotting are described in the <xref rid="mmc1" ref-type="supplementary-material">Supplemental Methods</xref>.</p></sec><sec id="sec1.14"><title>Statistical analysis</title><p id="p0105">Data are expressed as mean &#x000b1; SEM. Statistical significance (<italic>P&#x000a0;&#x0003c;</italic> 0.05) was determined using 1-way or 2-way analysis of variance followed by the Tukey post hoc test for multiple pairwise comparisons. Statistical analyses were performed using GraphPad Prism version 9.0.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Obesity evoked a decline in mitochondrial turnover and quality in human heart</title><p id="p0110">To discern biological processes in obese hearts, publicly available RNA sequencing result (GSE159612) from the Gene Expression Omnibus database containing myocardial tissues from subjects with different body mass index was analyzed. Gene Ontology analysis showed that the differentially expressed genes between heart samples from obese patients and normal subjects were overtly enriched in biological processes associated with intracellular Ca<sup>2+</sup> homeostasis, including &#x0201c;response to calcium ion&#x0201d; and &#x0201c;calcium-ion regulated exocytosis&#x0201d; (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1A</xref>). Gene set enrichment analysis was used to determine whether a series of prior defined sets of genes (eg, those from a specific Gene Ontology term or Kyoto Encyclopedia of Genes and Genomes pathway) was concordantly different between lean and obese individuals. Gene set enrichment analysis revealed that genes encoding Ca<sup>2+</sup> import into the mitochondria were consistently more abundant in obese than lean individuals, whereas other biological processes associated with Ca<sup>2+</sup> regulation, such as &#x0201c;Ca<sup>2+</sup> ion import into cytosol,&#x0201d; were down-regulated in obese compared with normal-weight human hearts (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1B to 1D</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Enrichment Analysis Result of Transcriptome and Mitochondrial Protein Profiles in the Human Heart</p><p><bold>(A)</bold> Bubble plot showing top enriched Gene Ontology (GO) terms of biological process. Gene set enrichment analysis (GSEA) result of <bold>(B)</bold> &#x0201c;Ca<sup>2+</sup> import into mitochondria&#x0201d; and <bold>(C)</bold> &#x0201c;Ca<sup>2+</sup> ion import into cytosol.&#x0201d; Distribution of genes in the ranked gene list is shown as &#x0201c;hits.&#x0201d; The enrichment score <bold>(green line)</bold> represents the running enrichment score at any point in the gene set. The <bold>bottom portion</bold> exhibits the value of ranking metric that measures a gene&#x02019;s correlation with a phenotype. <italic>P</italic>&#x000a0;values and the normalized enrichment score (NES) are presented in tabular format. <bold>(D)</bold> Ridge plot showing GSEA result of enriched biological processes (BPs) related to Ca<sup>2+</sup> (<italic>P&#x000a0;&#x0003c;</italic> 0.05, |NES| &#x0003e; 1). <bold>(E)</bold> Mitochondrial or mitophagy proteins (Parkin, LC3BII-I, p62, PGC1&#x003b1;, UCP2, and VDAC1) in lean and obese human hearts. GAPDH, &#x003b1;-tubulin, or COX IV was used as the loading control. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;6 to 8 samples/group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, and &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0115">Next, levels of proteins associated with mitochondrial Ca<sup>2+</sup> and mitochondrial quality control were evaluated in human heart samples. Consistent with the gene set enrichment analysis results, levels of VDAC1 were up-regulated along with down-regulated LC3BII/LC3BI ratio, Parkin, peroxisome proliferator&#x02013;activated receptor &#x003b3; coactivator 1&#x003b1; (a transcriptional coactivator of mitochondrial biogenesis), and uncoupling protein 2 (a predominant isoform of mitochondrial uncoupling protein), as well as increased accumulation of p62 in obese human hearts (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1E</xref>). These data provide evidence for dampened mitochondrial turnover (autophagy and biogenesis) and buildup of functionally compromised mitochondria in obese hearts.</p></sec><sec id="sec2.2"><title>Parkin deficiency did not affect global energy metabolism in response to HFD intake</title><p id="p0120">Parkin<sup>&#x02212;/&#x02212;</sup> and WT mice were fed an HFD for 24&#x000a0;weeks. The HFD evoked metabolic derangement, shown as decreased O<sub>2</sub> consumption, CO<sub>2</sub> production, respiratory exchange ratio, and heat production, without affecting physical activity, in a comparable manner in both WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2A to 2P</xref>). The lower energy expenditure in HFD-fed mice was not related to decreased physical activity (<xref rid="fig2" ref-type="fig">Figures&#x000a0;2O</xref> and <xref rid="fig2" ref-type="fig">2P</xref>). These findings suggested that HFD intake switched energy source with permission from carbohydrates to fats in WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice. Thus, Parkin deficiency does not affect HFD intake&#x02013;induced global metabolic disorder, ruling out global impact of Parkin on energy metabolism following HFD intake.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Metabolic Properties (During a 24-Hour Cycle) in WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice Fed an LFD or HFD for 24 Weeks</p><p><bold>(A)</bold> O<sub>2</sub> consumption (V<sc>o</sc><sub>2</sub>; 24 hours). <bold>(B)</bold> Pooled V<sc>o</sc><sub>2</sub> (light). <bold>(C)</bold> Pooled V<sc>o</sc><sub>2</sub> (dark). <bold>(D)</bold> Pooled V<sc>o</sc><sub>2</sub> (combined). <bold>(E)</bold> CO<sub>2</sub> production (V<sc>co</sc><sub>2</sub>; 24 hours). <bold>(F)</bold> Pooled V<sc>co</sc><sub>2</sub> (light). <bold>(G)</bold> Pooled V<sc>co</sc><sub>2</sub> (dark). <bold>(H)</bold> Pooled V<sc>co</sc><sub>2</sub> (combined). <bold>(I)</bold> Respiratory exchange ratio (RER; 24 hours). <bold>(J)</bold> Pooled RER (light). <bold>(K)</bold> Pooled RER (dark). <bold>(L)</bold> Pooled RER (combined). <bold>(M)</bold> Heat production (24 hours). <bold>(N)</bold> Pooled heat production. <bold>(O)</bold> Total physical activity (24 hours). <bold>(P)</bold> Pooled total physical activity. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;7 or 8 mice/group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05 vs WT-LFD group <bold>(A, E, I, M, O)</bold>; &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, and &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups <bold>(B to D, F to H, J to L, N, P)</bold>. HFD&#x000a0;=&#x000a0;high-fat diet; LFD&#x000a0;=&#x000a0;low-fat diet; WT&#x000a0;=&#x000a0;wild-type.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.3"><title>Biometrics, insulin resistance, and cardiac geometry of mice fed an LFD or HFD</title><p id="p0125">Consistent with metabolic cage data, body weight was comparably increased in WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice receiving the HFD (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3A</xref>). HFD consumption equally increased plasma levels of insulin and triglycerides without affecting fasting blood glucose levels in WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3B to 3D</xref>). Homeostasis model assessment&#x02013;estimated insulin resistance index exhibited comparably impaired insulin sensitivity in WT and Parkin<sup>&#x02212;/&#x02212;</sup> mice receiving the HFD (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3E</xref>). Interestingly, HFD-induced increases in gross heart weight were more pronounced in Parkin<sup>&#x02212;/&#x02212;</sup> mice compared with WT mice (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3F</xref>), indicating a potential role of Parkin in the maintenance of cardiac geometry in obesity. Although heart weight normalized to tibial length failed to reach statistical significance in HFD groups (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3G</xref>), Parkin ablation accentuated HFD intake&#x02013;provoked rises in cardiomyocyte cross-sectional area, intracardial accumulation of lipids, and interstitial fibrosis (<xref rid="fig3" ref-type="fig">Figures&#x000a0;3H to 3M</xref>). These data indicate that Parkin deficiency accentuates HFD intake&#x02013;induced cardiac remodeling and steatosis without affecting overall insulin sensitivity.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>HFD Intake&#x02013;Induced Body Weight Gain, Glucose Intolerance, Plasma Profile, and Cardiac Remodeling in WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice</p><p><bold>(A)</bold> Body weight gain over the 24-week feeding period. <bold>(B)</bold> Fasting blood glucose. <bold>(C)</bold> Serum triglycerides. <bold>(D)</bold> Plasma insulin. <bold>(E)</bold> Homeostasis model assessment&#x02013;estimated insulin resistance (HOMA-IR) index. <bold>(F)</bold> Heart weight. <bold>(G)</bold> Heart weight normalized to tibial length. <bold>(H)</bold> Representative images of lectin. <bold>(I)</bold>&#x000a0;Pooled cardiomyocyte cross-sectional area. <bold>(J)</bold> Representative images of Oil red O. <bold>(K)</bold> Pooled quantitative analysis of lipid content. <bold>(L)</bold> Representative images&#x000a0;of Masson trichrome staining. <bold>(M)</bold> Pooled quantitative analysis of interstitial fibrotic area (as a percentage of entire cardiac region). Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;5 to 7 mice/group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic>&#x000a0;0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, and &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups. Abbreviations as in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.4"><title>Parkin ablation worsened HFD-induced cardiac dysfunction without affecting vascular function</title><p id="p0130">Changes in cardiac systolic and diastolic function, cardiac geometry, and aortic stiffness were monitored using echocardiography. Although Parkin ablation alone did not affect echocardiographic parameters, it augmented HFD intake&#x02013;induced increases in LV end-systolic diameter and unmasked HFD-induced increase in LV end-diastolic diameter, in line with the exacerbated decline in fractional shortening and ejection fraction as well as increases in LV mass with HFD intake, without any notable changes in LV wall thickness, septal thickness, and heart rate (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4A to 4I</xref>). Parkin removal accentuated HFD-induced LV diastolic defect, as evidenced by a more pronounced decline in E/A ratio (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4J</xref>). However, deceleration time remained similar in all groups (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4K</xref>). In addition, HFD increased systolic but not diastolic BP (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4L and 4M</xref>) and promoted arterial stiffness (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4N and 4O</xref>) (as manifested by higher pulse-wave velocity values), the effects of which were unaffected by Parkin ablation. Parkin knockout itself did not affect BP and aortic stiffness (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4L to 4O</xref>). These findings denote that Parkin ablation augments HFD intake&#x02013;induced cardiac dysfunction and remodeling without affecting BP and aortic stiffness.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>HFD Intake&#x02013;Induced Changes in Echocardiographic Indexes in WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice</p><p><bold>(A)</bold> Representative echocardiographic images from 4 mouse groups. <bold>(B)</bold> Left ventricular (LV) wall thickness. <bold>(C)</bold> Septal thickness. <bold>(D)</bold> LV end-systolic diameter (LVESD). <bold>(E)</bold> LV end-diastolic diameter (LVEDD). <bold>(F)</bold> Fractional shortening. <bold>(G)</bold> Ejection fraction. <bold>(H)</bold> LV mass. <bold>(I)</bold> Heart rate. <bold>(J)</bold> E/A ratio. <bold>(K)</bold> Deceleration time (DT). <bold>(L)</bold> Diastolic blood pressure (BP). <bold>(M)</bold> Systolic BP. <bold>(N)</bold> Representative images of pulse-wave velocity (PWV). <bold>(O)</bold> PWV. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;7 to 9 mice/group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, or &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups. Abbreviations as in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>.</p></caption><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec2.5"><title>Parkin ablation aggravated cardiomyocyte contractile and intracellular Ca<sup>2+</sup> derangement in the face of HFD intake</title><p id="p0135">Neither the HFD nor Parkin ablation exhibited any notable responses on cardiomyocyte cell length (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5A</xref>). In comparison with LFD intake, HFD intake induced decreased peak shortening, maximal velocity of shortening and relengthening (&#x000b1;dL/dt), and prolonged relengthening duration (TR<sub>90</sub>) without affecting shortening duration (time to peak shortening), which were more pronounced in Parkin<sup>&#x02212;/&#x02212;</sup> mice compared with WT mice (<xref rid="fig5" ref-type="fig">Figures&#x000a0;5B to 5F</xref>). To decipher potential mechanisms underlying Parkin ablation&#x02013;elicited deterioration of HFD-induced cardiomyocyte dysfunction, intracellular Ca<sup>2+</sup> handling was evaluated using the Ca<sup>2+</sup>-sensitive fluorescence dye Fura-2. Parkin ablation overtly accentuated the HFD-provoked rise in basal intracellular Ca<sup>2+</sup> level, decrease of the electrically stimulated increase in intracellular Ca<sup>2+</sup> (change in Fura-2 fluorescence intensity), and prolongation of intracellular Ca<sup>2+</sup> clearance without any notable effect itself (<xref rid="fig5" ref-type="fig">Figures&#x000a0;5G to 5I</xref>).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Effect of HFD Intake on Cardiomyocyte Contractile and Intracellular Ca<sup>2+</sup> Properties in WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice</p><p><bold>(A)</bold> Resting cell length. <bold>(B)</bold> Peak shortening (percentage of resting cell length). <bold>(C)</bold> Maximal velocity of shortening (+dL/dt). <bold>(D)</bold> Maximal velocity of relengthening (&#x02212;dL/dt). <bold>(E)</bold> Time to peak shortening (TPS). <bold>(F)</bold> Time to 90% relengthening (TR<sub>90</sub>). <bold>(G)</bold> Baseline Fura-2 fluorescence intensity (FFI). <bold>(H)</bold> Increase in FFI (&#x00394;FFI) in response to electric stimuli. <bold>(I)</bold> Intracellular Ca<sup>2+</sup> decay rate. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;56 <bold>(A to F)</bold> or 40 <bold>(G to I)</bold> cells from 4 mice per group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, or &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic>&#x000a0;0.001 between indicated groups. Abbreviations as in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>.</p></caption><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec2.6"><title>HFD intake&#x02013;induced mitochondrial injury and ROS accumulation were accentuated in Parkin<sup>&#x02212;/&#x02212;</sup> mice</title><p id="p0140">Given the role of Parkin-mediated mitophagy in mitochondrial quality control,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> mitochondrial morphology and function were examined. Parkin<sup>&#x02212;/&#x02212;</sup> mice displayed greater cytoarchitectural aberrations as a consequence of HFD intake compared with WT mice, such as mitochondrial swelling, fragmentation of cristae, and distortion of sarcomeres and myocardial filaments on transmission electron microscopic analysis, with little ultrastructural change from Parkin ablation itself (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6A</xref>). Parkin<sup>&#x02212;/&#x02212;</sup> mice exhibited higher mitochondrial density, depicting accumulation of damaged mitochondria and reduced circulatory index (mitochondrial major axis length/minor axis length), with little change in area per mitochondria in response to HFD intake (<xref rid="fig6" ref-type="fig">Figures&#x000a0;6D to 6F</xref>). Likewise, HFD intake promoted mitochondrial ROS production with a more pronounced response in Parkin<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="fig6" ref-type="fig">Figures&#x000a0;6B, 6C, 6G, and 6H</xref>). Furthermore, our data demonstrated more pronounced increases in mitochondrial Ca<sup>2+</sup> in hearts from Parkin<sup>&#x02212;/&#x02212;</sup> mice following HFD intake compared with WT mice (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6I</xref>). Sustained mitochondrial Ca<sup>2+</sup> overload triggers mPTP opening, resulting in rapid dissipation of proton gradient across the inner mitochondrial membrane, which drives energetic deficits and cell death.<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> Our data revealed that Parkin deletion accentuated HFD-induced mPTP opening, as evidenced by NAD<sup>+</sup> levels (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6J</xref>), suggesting a possible role for Parkin-mediated mitochondrial Ca<sup>2+</sup> overload and mPTP opening in HFD-induced cardiac injury. In line with the loss of mitochondrial aconitase activity (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6K</xref>), Parkin deletion accentuated HFD intake&#x02013;induced changes in PGC1&#x003b1;, UCP2, and TOM20 (<xref rid="fig6" ref-type="fig">Figures&#x000a0;6L to 6O</xref>). These data reveal that Parkin deficiency impairs mitochondrial integrity and increased oxidative stress, leading to disruption of mitochondrial function upon HFD consumption.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Effect of HFD Intake on Myocardial Ultrastructure, Mitochondrial O<sub>2</sub><sup>&#x02212;</sup> Production, Mitochondrial Respiration, and Mitochondrial Integrity in WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice</p><p><bold>(A)</bold> Representative transmission electron microscopic (TEM) images of mitochondrial ultrastructure. <bold>(B)</bold> Representative dihydroethidium (DHE) fluorescence images. <bold>(C)</bold>&#x000a0;Representative MitoSOX fluorescence images. <bold>(D)</bold> Mitochondrial area (percentage total area). <bold>(E)</bold> Mitochondrial area (per mitochondrion). <bold>(F)</bold> Mitochondrial circularity index (major axis length/minor axis length). <bold>(G, H)</bold> Pooled data of mitochondrial reactive oxygen species levels using DHE staining or MitoSOX staining. <bold>(I)</bold>&#x000a0;Baseline mitochondrial Ca<sup>2+</sup> levels using Rhod-2. <bold>(J)</bold> NAD<sup>+</sup> level depicting mitochondrial permeability transition pore opening. <bold>(K)</bold> Mitochondrial aconitase activity. <bold>(L)</bold> Representative immunoblots of UCP2, PGC1&#x003b1;, and TOM20. GAPDH or &#x003b1;-tubulin was used as the loading control. Quantified mitochondrial protein levels of <bold>(M)</bold>&#x000a0;UCP2, <bold>(N)</bold> PGC1&#x003b1;, and <bold>(O)</bold> TOM20. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;6 or 7 mice <bold>(A to H, J to O)</bold> or 15 cells from 4 mice <bold>(I)</bold> per group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, or &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups. Abbreviations as in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>.</p></caption><graphic xlink:href="gr6"/></fig></p></sec><sec id="sec2.7"><title>HFD-induced changes in autophagy and mitophagy and mitochondria-mediated cell death were augmented by Parkin ablation</title><p id="p0145">Treatment of PA or Parkin knockdown with small interfering RNA significantly suppressed mitophagy, while Parkin overexpression rescued PA-induced loss of mitophagy in AMCMs (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7A and 7B</xref>). Parkin deletion augmented HFD-induced autophagy loss with little effect itself (LC3BII/LC3BI ratio and p62) in mice (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7C and 7D</xref>). Parkin was slightly suppressed in murine hearts following the 24-week HFD feeding (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7E</xref>). HFD evoked overt production of inflammatory cytokines, including IL-6 and TNF-&#x003b1;, the effect of which was further enhanced by Parkin ablation, without any effect from Parkin knockout itself (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7F and 7G</xref>).<fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Effect of HFD Intake on Autophagy, Mitophagy, and Mitochondria-Mediated Cell Death in Hearts From WT and Parkin<sup>&#x02212;/&#x02212;</sup> Mice</p><p><bold>(A)</bold> Representative images of mt-Keima. <bold>(B)</bold> Pooled data of mt-Keima fluorescence signal (561&#x000a0;nm/458&#x000a0;nm). Quantified protein levels and representative immunoblots as insets of <bold>(C)</bold> LC3BI/II, <bold>(D)</bold> p62, <bold>(E)</bold> Parkin, <bold>(F)</bold> IL-6, <bold>(G)</bold> TNF-&#x003b1;, <bold>(H)</bold> FasL, <bold>(I)</bold> caspase-8, <bold>(J)</bold> Bax, <bold>(K)</bold> Bcl-2, <bold>(L)</bold> cytosolic apoptosis-inducing factor (AIF), <bold>(M)</bold> cytosolic cytochrome <italic>c</italic>, <bold>(N)</bold> mitochondrial cytochrome <italic>c</italic>, <bold>(O)</bold> caspase-9, and <bold>(P)</bold> caspase-3. GAPDH, &#x003b1;-tubulin, or COX IV was used as the loading control. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;10 images <bold>(A, B)</bold> or 5 to 7 mice <bold>(C to P)</bold> per group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, or &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups. OE&#x000a0;=&#x000a0;overexpression; PA&#x000a0;=&#x000a0;palmitic acid; siRNA&#x000a0;=&#x000a0;small interfering RNA; other abbreviations as in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>.</p></caption><graphic xlink:href="gr7"/></fig></p><p id="p0150">Regulated cell death involves cell surface death receptors or damaged mitochondria.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Our data revealed that death receptor Fas ligand was unaffected by HFD intake, and caspase-8 was comparably up-regulated in the hearts of Parkin<sup>&#x02212;/&#x02212;</sup> and WT mice following HFD intake (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7H and 7I</xref>), indicating less likely any involvement of death receptor-mediated apoptosis in Parkin deletion&#x02013;accentuated anomalies following HFD intake.</p><p id="p0155">Execution of mitochondria-dependent apoptosis involves mitochondrial outer membrane permeabilization, which is tightly regulated by the B cell lymphoma-2 (BCL-2) family of proteins.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> We noted activation of pro&#x02013;cell death protein Bax and suppression of prosurvival Bcl-2 following HFD consumption, with a more profound response in Parkin<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7J and 7K</xref>). Induction of mitochondrial outer membrane permeabilization triggers cell death through release of mitochondrial proapoptotic factors such as cytochrome <italic>c</italic> and apoptosis-inducing factor. Release of cytochrome <italic>c</italic> and apoptosis-inducing factor from mitochondria to cytosol was increased following HFD intake, with a more abrupt rise in Parkin<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7L to 7N</xref>). Parkin ablation augmented activation of caspase-9 and caspase-3 following release of cytochrome <italic>c</italic> in face of HFD intake (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7O and 7P</xref>). Thus, loss of Parkin deteriorates mitochondria-dependent apoptosis following HFD intake.</p></sec><sec id="sec2.8"><title>Parkin regulated HFD-induced mitochondrial Ca<sup>2+</sup> overload through proteasome-dependent degradation of VDAC1</title><p id="p0160">Our data revealed that HFD intake led to mitochondrial Ca<sup>2+</sup> overload and mPTP opening, culminating in cell death. To this end, levels of VDAC isoforms and MCU complex, which gate import of Ca<sup>2+</sup> in outer mitochondrial membrane and inner mitochondrial membrane, respectively,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> were examined. Our data demonstrated that only VDAC1 was further up-regulated in hearts from Parkin<sup>&#x02212;/&#x02212;</sup> mice following HFD intake compared with WT mice (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8A</xref>), while VDAC2, VDAC3, MCU, MICU1, MICU2, and MCUb were unchanged or equally affected by HFD intake (<xref rid="fig8" ref-type="fig">Figures&#x000a0;8B to 8G</xref>). Thus, Parkin deficiency amplified HFD-induced mitochondrial Ca<sup>2+</sup> overload, possibly through regulating VDAC1 to stimulate mitochondria-mediated cell death.<fig id="fig8"><label>Figure&#x000a0;8</label><caption><p>Effect Of Parkin On Mitochondrial Ca<sup>2+</sup> Transport Protein Levels</p><p><bold>(A)</bold> Ca<sup>2+</sup> channel in the outer mitochondrial membrane VDAC1. <bold>(B)</bold> VDAC2. <bold>(C)</bold> VDAC3. <bold>(D)</bold> Mitochondrial inner membrane Ca<sup>2+</sup> uniporter subunit mitochondrial Ca<sup>2+</sup> uniporter (MCU). <bold>(E)</bold> MICU1. <bold>(F)</bold> MICU2. <bold>(G)</bold> MCUb. <bold>Insets</bold> show representative immunoblots depicting protein levels with GAPDH or &#x003b1;-tubulin as the loading control. <bold>(H)</bold>&#x000a0;Scheme depicting protein degradation pathways and inhibitors. <bold>(I, J)</bold> Adult murine cardiomyocytes were transduced with LacZ or Parkin adenovirus for 48 hours prior to treatment with proteasome inhibitor MG132 (10&#x000a0;&#x003bc;M, 18 hours), autophagy inhibitor 3-MA (5&#x000a0;mM/L, 18 hours), or lysosome inhibitor bafilomycin A1 (50&#x000a0;nM, 4&#x000a0;hours) in the presence or absence of PA (0.5&#x000a0;mM, 8 hours). <bold>(I)</bold> Representative immunoblots depicting protein levels of VDAC1 and Parkin. &#x003b1;-Tubulin was used as the loading control. <bold>(J)</bold> Quantified VDAC1 protein level. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;5 to 7 mice/group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, and &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups <bold>(A to G)</bold> or vs vehicle control <bold>(J)</bold>. ###<italic>P&#x000a0;&#x0003c;</italic> 0.001 vs vehicle-PA-LacZ <bold>(J)</bold>. Abbreviations as in <xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref> and <xref rid="fig7" ref-type="fig">7</xref>.</p></caption><graphic xlink:href="gr8"/></fig></p><p id="p0165">Parkin promotes ubiquitination and degradation of mitochondrial proteins.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> These ubiquitinated proteins were subsequently subjected to proteasome-dependent degradation or removal by autophagy machinery<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8H</xref>). VDAC1 is a perceived substrate for Parkin-mediated ubiquitination.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> We examined the effect of Parkin on VDAC1 in response to PA in mouse cardiomyocytes using Parkin adenoviral transfection. Our data revealed that Parkin effectively rescued the rise in VDAC1 level evoked by PA (0.5&#x000a0;mM for 8 hours) (<xref rid="fig8" ref-type="fig">Figures&#x000a0;8I and 8J</xref>, lanes 1 to 3). Next, cardiomyocytes were treated with the proteasome inhibitor MG132, the autophagy inhibitor 3-MA, or the lysosome inhibitor bafilomycin A1 to determine the underlying modalities of Parkin-mediated VDAC1 degradation (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8H</xref>). MG132 treatment up-regulated VDAC1 in the absence of PA and abolished Parkin-evoked VDAC1 degradation in the presence of PA, while autophagy inhibition did not affect basal or Parkin-induced changes in VDAC1 levels (<xref rid="fig8" ref-type="fig">Figures&#x000a0;8I and 8J</xref>). These results suggest that insufficiency in both Parkin and Parkin-mediated degradation of VDAC1 by the ubiquitin-proteasome system may contribute to HFD-induced mitochondrial Ca<sup>2+</sup> overload.</p></sec><sec id="sec2.9"><title>Parkin protected HFD-induced mitochondrial Ca<sup>2+</sup> overload and contractile dysfunction</title><p id="p0170">A cohort of adult mouse cardiomyocytes was transfected with Parkin overnight prior to challenge with PA (0.5&#x000a0;mM for 8 hours) in the presence or absence of pharmacologic agents to evaluate cardiomyocyte contractile function and mitochondrial Ca<sup>2+</sup> levels. Our data showed that PA significantly elevated mitochondrial Ca<sup>2+</sup> levels and impaired cardiomyocyte function, whereas Parkin overexpression or the VDAC1 inhibitor DIDS reversed mitochondrial Ca<sup>2+</sup> overload (<xref rid="fig9" ref-type="fig">Figures&#x000a0;9A and 9B</xref>) and contractile dysfunction (decreased peak shortening, &#x000b1;dL/dt, prolonged TR<sub>90</sub>) induced by PA (<xref rid="fig9" ref-type="fig">Figures&#x000a0;9C to 9H</xref>).<fig id="fig9"><label>Figure&#x000a0;9</label><caption><p>Effect of Parkin Transfection and Interventions of VDAC1 or Mitochondrial Permeability Transition Pore Opening on PA-Induced Changes in Ca<sup>2+</sup> Homeostasis and Cardiomyocyte Contractile Function</p><p>Adult mouse cardiomyocytes were transfected with Parkin using adenovirus (Parkin OE) overnight prior to incubation with PA (0.5&#x000a0;mM) for another 8 hours in the presence or absence of the VDAC1 inhibitor DIDS (200&#x000a0;&#x003bc;M, 1 hour), mitochondrial permeability transition pore opening activator HA14-1 (2&#x000a0;&#x003bc;M, 24 hours), or cisplatin (20&#x000a0;&#x003bc;M, 24 hours). <bold>(A)</bold> Representative confocal microscopic images of mitochondrial Ca<sup>2+</sup> fluorescence in adult murine cardiomyocytes stained with Rhod-2 <bold>(red)</bold>. <bold>(B)</bold> Quantified Rhod-2 fluorescent intensity. <bold>(C)</bold> Resting cell length. <bold>(D)</bold> Peak shortening (percentage of resting cell length). <bold>(E)</bold> Maximal velocity of shortening (+dL/dt). <bold>(F)</bold> Maximal velocity of relengthening (&#x02212;dL/dt). <bold>(G)</bold> TPS. <bold>(H)</bold> TR<sub>90</sub>. Mean &#x000b1; SEM, n&#x000a0;=&#x000a0;10 cells from 4 mice <bold>(A, B)</bold> or 20 cells from 4 mice <bold>(C&#x000a0;to&#x000a0;H)</bold> per group. &#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.05, &#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.01, and &#x02217;&#x02217;&#x02217;<italic>P&#x000a0;&#x0003c;</italic> 0.001 between indicated groups. Abbreviations as in <xref rid="fig2" ref-type="fig">Figures&#x000a0;2</xref>, <xref rid="fig5" ref-type="fig">5</xref>, and <xref rid="fig7" ref-type="fig">7</xref>.</p></caption><graphic xlink:href="gr9"/></fig></p><p id="p0175">mPTP opening is vital for mitochondria-mediated cell death, where the inner mitochondrial membrane allows free passage of solutes up to 1.5&#x000a0;kDa in size and ultimately triggers cell death.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Inhibition of Bcl-2 using HA14-1 sensitizes mPTP opening in high-Ca<sup>2+</sup> environments,<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> and cisplatin induces mitochondrial Ca<sup>2+</sup> overload and mPTP opening.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Although low-dose HA14-1 or cisplatin alone did not exert any effects on mitochondrial Ca<sup>2+</sup> load and contractile function, Parkin-evoked benefits on cardiomyocyte mitochondrial Ca<sup>2+</sup> and contractile function were obliterated by HA14-1 or cisplatin (<xref rid="fig9" ref-type="fig">Figures&#x000a0;9C to 9H</xref>). None of the pharmacologic agents or viral vector affected cardiomyocyte function and mitochondrial Ca<sup>2+</sup> levels (<xref rid="fig9" ref-type="fig">Figures&#x000a0;9A to 9H</xref>). Taken together, exogenous Parkin expression or VDAC1 inhibition protects cardiomyocytes from PA-induced contractile dysfunction through inhibition of mitochondrial Ca<sup>2+</sup> overload and mPTP opening.</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0180">Our salient findings reveal that Parkin deficiency accentuates HFD-evoked cardiac remodeling and dysfunction, mitochondrial Ca<sup>2+</sup> overload, as well as mitochondria-dependent cell death, with no impact on insulin sensitivity, global energy metabolism, aortic stiffness, and BP with either LFD or HFD intake. Furthermore, Parkin-mediated proteasome-dependent degradation of VDAC1 may be responsible for these unfavorable effects. These findings favor a unique role for the Parkin-VDAC1 axis as a therapeutic target in obesity-induced cardiac anomalies, possibly through mitochondrial Ca<sup>2+</sup> regulation.</p><p id="p0185">A wealth of research has documented obesity-induced unfavorable myocardial geometric and functional changes, including cardiac hypertrophy, interstitial fibrosis, compromised cardiac contractility, and prolonged diastole, along with higher BP and vascular dysfunction.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> This is consistent with our observations of cardiac hypertrophy (increased LV mass and chamber size), interstitial fibrosis, reduced fractional shortening, ejection fraction, E/A ratio, peak shortening, &#x000b1;dL/dt, prolonged TR<sub>90</sub>, elevated BP, and increased pulse-wave velocity following 24-week HFD intake. In general, sustained obesity contributes to cardiomyopathy characterized by diastolic dysfunction.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Besides diastolic dysfunction manifested by a decreased E/A ratio, our data also noted that LV fractional shortening and ejection fraction were significantly decreased following 24-week HFD feeding, in line with earlier observations of long-term obesity.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref></p><p id="p0190">In our hands, a tight link is evident between Ca<sup>2+</sup> disturbance and mitochondrial injury in the realm of lipotoxic cardiac dysfunction, with a more pronounced change in Parkin<sup>&#x02212;/&#x02212;</sup> mice. Parkin plays a crucial role as an adaptor in maintaining the integrity of mitochondrial structure and function in the heart.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Previous studies have shown that Parkin prevents myocardial ischemia-reperfusion injury and hypoxia-mediated cell death.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> However, there is an inconsistency with regard to the precise role of mitophagy in HFD intake&#x02013;induced cardiac injuries. Tong et&#x000a0;al<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> found that cardiac autophagic flux in mice fed an HFD peaked at 6&#x000a0;weeks and later declined over time, while elevated mitophagy was observed as early as 3&#x000a0;weeks after the start of the HFD and lasted for 8&#x000a0;weeks. In contrast, we and others have noted declined mitophagy regulators, including Parkin and FUNDC1, in the heart after longer (12&#x000a0;weeks<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> or 20&#x000a0;weeks<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>) HFD feeding. Mitophagy, evaluated by mt-Keima, was also suppressed by PA treatment in isolated cardiomyocytes. Taken together, Parkin and mitophagy seem to be elevated at early stages of HFD-induced heart injury but decline over time.</p><p id="p0195">Given that patients usually manifest cardiac dysfunction after a long period of obesity,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> declined Parkin may play an essential role at advanced stages of obesity cardiomyopathy. Indeed, our data reveal that Parkin ablation accentuates HFD-induced unfavorable myocardial responses, including cardiac remodeling as well as systolic and diastolic dysfunction. It was reported that Parkin<sup>&#x02212;/&#x02212;</sup> mice were resistant to 6-week HFD feeding&#x02013;induced body weight gain.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> However, after long-term HFD feeding, Parkin<sup>&#x02212;/&#x02212;</sup> mice gained weight in our present study. Furthermore, HFD intake&#x02013;induced insulin resistance, metabolic derangement, elevated BP, and aortic stiffness are not affected by Parkin ablation, ruling out possible contributions from global and vascular effects of Parkin ablation.</p><p id="p0200">A number of scenarios should be considered for Parkin ablation&#x02013;induced exacerbation of cardiac remodeling and dysfunction under HFD intake. Our data highlights an essential role of Parkin in the regulation of Ca<sup>2+</sup> homeostasis, consistent with the Gene Expression Omnibus sequencing data from lean and obese human hearts. The correlation between mitochondrial Ca<sup>2+</sup> overload and impaired cardiac function has been extensively examined. Leaky type 2 ryanodine receptors on sarcoplasmic reticulum caused mitochondrial Ca<sup>2+</sup> overload and cardiac dysfunction in heart failure.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Knockdown of PKD2L1 led to exacerbated mitochondrial Ca<sup>2+</sup> overload and cardiac hypertrophy following high salt loading.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Overexpression of SERCA2a alleviated cardiac microvascular ischemic injury through suppressing Mfn2-mediated mitochondrial Ca<sup>2+</sup> import from endoplasmic reticulum.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Decreased Parkin upstream initiator PINK1 in the heart during sepsis led to defective mitochondrial Ca<sup>2+</sup> efflux and cardiomyocyte injury.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> Furthermore, mounting evidence from liver, adipose tissues, and macrophages has illustrated a role for Ca<sup>2+</sup> defect in obesity.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> For example, HFD-induced prolonged elevation of cytosolic Ca<sup>2+</sup> was responsible for autophagy defects in the liver.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> Recently, several attempts have been made to clarify the regulation of HFD-induced Ca<sup>2+</sup> overload in the heart. Our laboratory reported that loss of FUNDC1 accentuated HFD-induced mitochondrial Ca<sup>2+</sup> overload and cardiac dysfunction through interacting with FBXL2 to govern degradation of the endoplasmic reticulum Ca<sup>2+</sup> channel IP3R3.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> However, the underlying mechanism involved in mitochondrial Ca<sup>2+</sup> import, such as the Ca<sup>2+</sup> transporter VDAC1 and MCU complex, in the context of obesity remains unclear. Our results also demonstrate a crucial role for mitochondrial ROS production, mitochondrial injury, inflammation, as well as mitochondria-mediated (not death receptor&#x02013;mediated) cell death in Parkin deficiency&#x02013;accentuated cardiac injury following HFD intake, denoting a vital role for mitochondrial injury and cell death in Parkin deficiency&#x02013;induced cardiac anomalies in obesity.</p><p id="p0205">Parkin, as a E3 ligase, directly binds to and ubiquitinates mitochondrial Ca<sup>2+</sup> import proteins, including VDAC isoforms and MCU complex.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> We found that lack of Parkin-mediated degradation may account for the buildup of mitochondrial Ca<sup>2+</sup> import protein VDAC1 rather than other isoforms of VDAC or MCU complex. Previous studies have indicated a pivotal role of VDAC1 in mitochondrial integrity and cardiac function. Restoration of VDAC1-HK2 interaction prevented mPTP opening and cell death in microvascular ischemia-reperfusion injury.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> Liproxstatin-1 inhibited ferroptosis and promoted cardiomyocyte survival through reducing VDAC1 levels, but not VDAC2/3.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Although VDAC1 is well known as a target for Parkin-mediated Lys 27 polyubiquitination and subsequent mitophagy,<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> it can also be degraded by the ubiquitin-proteasome system.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Our data confirmed that the protective effect of Parkin was obliterated by the proteasome inhibitor MG132, but not autophagy inhibitors. Recently, the proteolysis-targeting chimeras have demonstrated promise to selectively modulate protein content through the ubiquitin-proteasome system.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Our findings favor the utility of targeting Parkin and VDAC1 for mitochondrial Ca<sup>2+</sup> derangement and cardiac anomalies in obesity.</p><sec id="sec3.1"><title>Study limitations</title><p id="p0210">First, cisplatin was used to stimulate mitochondrial Ca<sup>2+</sup> overload and mPTP opening, although it can also bind with DNA and evoke DNA damage culminating in mitochondrial apoptosis.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Next, concurrent presence of diastolic and systolic dysfunction was observed in our HFD-induced obesity model. Given that diastolic dysfunction usually occurs prior to onset of systolic dysfunction,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> will deficiency in Parkin accelerate this process? Finally, Parkin is expressed in nearly all tissues, and a cardiac-specific knockout murine model would be more advantageous to directly address the role of Parkin in obesity cardiomyopathy in a more tissue-specific manner.</p></sec></sec><sec id="sec4"><title>Conclusions</title><p id="p0215">Findings from our present study provide evidence for the first time that Parkin deficiency accentuates HFD-induced cardiac anomalies but not aortic stiffness and BP change, likely through Parkin-VDAC1&#x02013;dependent regulation of mitochondrial Ca<sup>2+</sup> and mitochondrial integrity. Comprehensive evaluation of the role of Parkin in HFD-induced cardiac dysfunction rules out possible contribution from global metabolism on Parkin loss&#x02013;accentuated cardiac anomalies. These findings favor the notion that Parkin, VDAC1, and mitochondria Ca<sup>2+</sup> may serve as possible targets for drug development for heart dysfunction in patients with obesity. Further study is warranted to unveil the precise mechanism behind regulation of mitochondrial Ca<sup>2+</sup> mobilization in a clinically relevant setting of obesity heart anomalies.</p></sec><sec sec-type="COI-statement"><title>Funding Support and Author Disclosures</title><p id="p0220">This work was supported by the National Natural Science Foundation of China (grants 82130011, 81900233, and 81770261). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.<boxed-text id="dtbox1"><label>Perspectives</label><p id="p0225"><bold>COMPETENCY IN MEDICAL KNOWLEDGE:</bold> This study highlights that mitochondrial Ca<sup>2+</sup> overload is one of the major candidates for obesity-induced mitochondria-mediated cell death, cardiac dysfunction, and remodeling. Activating Parkin-mediated degradation of VDAC1 in cardiomyocytes attenuates contractile dysfunction by limiting mitochondrial Ca<sup>2+</sup> overload.</p><p id="p0230"><bold>TRANSLATIONAL OUTLOOK:</bold> Future studies are warranted to determine the potential therapeutic benefit of Parkin activation and suppression of mitochondrial Ca<sup>2+</sup> import, especially by promoting selective proteolysis of VDAC1, in cardiomyocytes for the prevention of cardiac remodeling and heart failure in the context of chronic obesity.</p></boxed-text></p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Piche</surname><given-names>M.E.</given-names></name><name><surname>Tchernof</surname><given-names>A.</given-names></name><name><surname>Despres</surname><given-names>J.P.</given-names></name></person-group><article-title>Obesity phenotypes, diabetes, and cardiovascular diseases</article-title><source>Circ Res</source><volume>126</volume><year>2020</year><fpage>1477</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">32437302</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Epigenetics and obesity cardiomyopathy: from pathophysiology to prevention and management</article-title><source>Pharmacol Ther</source><volume>161</volume><year>2016</year><fpage>52</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">27013344</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>N.N.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Sowers</surname><given-names>J.R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications</article-title><source>Physiol Rev</source><volume>101</volume><year>2021</year><fpage>1745</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">33949876</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Raffaello</surname><given-names>A.</given-names></name><name><surname>Mammucari</surname><given-names>C.</given-names></name><name><surname>Gherardi</surname><given-names>G.</given-names></name><name><surname>Rizzuto</surname><given-names>R.</given-names></name></person-group><article-title>Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes</article-title><source>Trends Biochem Sci</source><volume>41</volume><year>2016</year><fpage>1035</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">27692849</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>A.P.</given-names></name><name><surname>Hotamisligil</surname><given-names>G.S.</given-names></name></person-group><article-title>Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes</article-title><source>Cell Metab</source><volume>22</volume><year>2015</year><fpage>381</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">26190652</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Wong</surname><given-names>Y.C.</given-names></name><name><surname>Krainc</surname><given-names>D.</given-names></name></person-group><article-title>Mitochondria-lysosome contacts regulate mitochondrial Ca<sup>2+</sup> dynamics via lysosomal TRPML1</article-title><source>Proc Natl Acad Sci U S A</source><volume>117</volume><year>2020</year><fpage>19266</fpage><lpage>19275</lpage><pub-id pub-id-type="pmid">32703809</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>G.W.</given-names><suffix>II</suffix></name><name><surname>Kitsis</surname><given-names>R.N.</given-names></name></person-group><article-title>The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble</article-title><source>Circ Res</source><volume>116</volume><year>2015</year><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">25323859</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Tait</surname><given-names>S.W.</given-names></name><name><surname>Green</surname><given-names>D.R.</given-names></name></person-group><article-title>Mitochondrial regulation of cell death</article-title><source>Cold Spring Harb Perspect Biol</source><volume>5</volume><year>2013</year><object-id pub-id-type="publisher-id">a008706</object-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>D.</given-names></name><name><surname>Kolwicz</surname><given-names>S.C.</given-names><suffix>Jr.</suffix></name><name><surname>Wang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Increasing fatty acid oxidation prevents high-fat diet-induced cardiomyopathy through regulating Parkin-mediated mitophagy</article-title><source>Circulation</source><volume>142</volume><year>2020</year><fpage>983</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">32597196</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.X.</given-names></name><name><surname>Cui</surname><given-names>S.M.</given-names></name><name><surname>Zhang</surname><given-names>Y.M.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Mitochondrial Ca<sup>2+</sup> regulation in the etiology of heart failure: physiological and pathophysiological implications</article-title><source>Acta Pharmacol Sin</source><volume>41</volume><year>2020</year><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">32694759</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Turdi</surname><given-names>S.</given-names></name><name><surname>Ge</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>N.</given-names></name><name><surname>Bradley</surname><given-names>K.M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Interaction between maternal and postnatal high fat diet leads to a greater risk of myocardial dysfunction in offspring via enhanced lipotoxicity, IRS-1 serine phosphorylation and mitochondrial defects</article-title><source>J&#x000a0;Mol Cell Cardiol</source><volume>55</volume><year>2013</year><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">23266593</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Turdi</surname><given-names>S.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Adiponectin knockout accentuates high fat diet-induced obesity and cardiac dysfunction: role of autophagy</article-title><source>Biochim Biophys Acta</source><volume>1832</volume><year>2013</year><fpage>1136</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">23524376</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Ceylan-Isik</surname><given-names>A.F.</given-names></name><name><surname>Kandadi</surname><given-names>M.R.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction</article-title><source>J&#x000a0;Mol Cell Cardiol</source><volume>63</volume><year>2013</year><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">23859766</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.Z.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Age-associated sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm</article-title><source>Circ Res</source><volume>119</volume><year>2016</year><fpage>1076</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">27650558</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Ackers-Johnson</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>P.Y.</given-names></name><name><surname>Holmes</surname><given-names>A.P.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S.M.</given-names></name><name><surname>Pavlovic</surname><given-names>D.</given-names></name><name><surname>Foo</surname><given-names>R.S.</given-names></name></person-group><article-title>A&#x000a0;simplified, Langendorff-free method for concomitant isolation of viable cardiac myocytes and nonmyocytes from the adult mouse heart</article-title><source>Circ Res</source><volume>119</volume><year>2016</year><fpage>909</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">27502479</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>TAX1BP1 Protects against myocardial infarction-associated cardiac anomalies through inhibition of inflammasomes in a RNF34/MAVS/NLRP3-dependent manner</article-title><source>Sci Bull</source><volume>66</volume><issue>16</issue><year>2021</year><fpage>1669</fpage><lpage>1683</lpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>A.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy</article-title><source>J&#x000a0;Mol Cell Cardiol</source><volume>71</volume><year>2014</year><fpage>92</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">24434637</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>N.</given-names></name><name><surname>Hua</surname><given-names>Y.</given-names></name><name><surname>Richmond</surname><given-names>K.L.</given-names></name><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Cardiac overexpression of metallothionein rescues cold exposure-induced myocardial contractile dysfunction through attenuation of cardiac fibrosis despite cardiomyocyte mechanical anomalies</article-title><source>Free Rad Biol Med</source><volume>53</volume><year>2012</year><fpage>194</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">22565031</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mitochondrial Ca<sup>2+</sup> flux modulates spontaneous electrical activity in ventricular cardiomyocytes</article-title><source>PLoS ONE</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0200448</object-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Ge</surname><given-names>W.</given-names></name><name><surname>Harns</surname><given-names>C.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoRI-HDAC1-mediated regulation of autophagy</article-title><source>J&#x000a0;Mol Cell Cardiol</source><volume>119</volume><year>2018</year><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">29660306</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Malide</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Rovira</surname><suffix>II</suffix></name><name><surname>Combs</surname><given-names>C.A.</given-names></name><name><surname>Finkel</surname><given-names>T.</given-names></name></person-group><article-title>A&#x000a0;fluorescence-based imaging method to measure in&#x000a0;vitro and in&#x000a0;vivo mitophagy using mt-Keima</article-title><source>Nat Protoc</source><volume>12</volume><year>2017</year><fpage>1576</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">28703790</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Ajoolabady</surname><given-names>A.</given-names></name><name><surname>Aslkhodapasandhokmabad</surname><given-names>H.</given-names></name><name><surname>Aghanejad</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Mitophagy receptors and mediators: therapeutic targets in the management of cardiovascular ageing</article-title><source>Ageing Res Rev</source><volume>62</volume><year>2020</year><fpage>101129</fpage><pub-id pub-id-type="pmid">32711157</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N.N.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Mitophagy, mitochondrial dynamics, and homeostasis in cardiovascular aging</article-title><source>Oxid Med Cell Longev</source><volume>2019</volume><year>2019</year><fpage>9825061</fpage><pub-id pub-id-type="pmid">31781358</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Del Re</surname><given-names>D.P.</given-names></name><name><surname>Amgalan</surname><given-names>D.</given-names></name><name><surname>Linkermann</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Kitsis</surname><given-names>R.N.</given-names></name></person-group><article-title>Fundamental mechanisms of regulated cell death and implications for heart disease</article-title><source>Physiol Rev</source><volume>99</volume><year>2019</year><fpage>1765</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">31364924</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>J.Q.</given-names></name><name><surname>Molkentin</surname><given-names>J.D.</given-names></name></person-group><article-title>Physiological and pathological roles of the mitochondrial permeability transition pore in the heart</article-title><source>Cell Metab</source><volume>21</volume><year>2015</year><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">25651175</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>T.M.</given-names></name><name><surname>Murphy</surname><given-names>E.</given-names></name></person-group><article-title>Role of mitochondrial calcium and the permeability transition pore in regulating cell death</article-title><source>Circ Res</source><volume>126</volume><year>2020</year><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">31944918</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Shoshan-Barmatz</surname><given-names>V.</given-names></name><name><surname>Shteinfer-Kuzmine</surname><given-names>A.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name></person-group><article-title>VDAC1 at the intersection of cell metabolism, apoptosis, and diseases</article-title><source>Biomolecules</source><volume>10</volume><year>2020</year><fpage>1485</fpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Barazzuol</surname><given-names>L.</given-names></name><name><surname>Giamogante</surname><given-names>F.</given-names></name><name><surname>Brini</surname><given-names>M.</given-names></name><name><surname>Cal&#x000ec;</surname><given-names>T.</given-names></name></person-group><article-title>PINK1/Parkin mediated mitophagy, Ca<sup>2+</sup> signalling, and ER-mitochondria contacts in Parkinson&#x02019;s disease</article-title><source>Int J Mol Sci</source><volume>21</volume><year>2020</year><fpage>1772</fpage></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Inhibition of Bcl-2 sensitizes mitochondrial permeability transition pore (MPTP) opening in ischemia-damaged mitochondria</article-title><source>PLoS ONE</source><volume>10</volume><year>2015</year><object-id pub-id-type="publisher-id">e0118834</object-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis</article-title><source>Oncol Rep</source><volume>34</volume><year>2015</year><fpage>3051</fpage><lpage>3060</lpage><pub-id pub-id-type="pmid">26398138</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Sharaf el dein</surname><given-names>O.</given-names></name><name><surname>Gallerne</surname><given-names>C.</given-names></name><name><surname>Brenner</surname><given-names>C.</given-names></name><name><surname>Lemaire</surname><given-names>C.</given-names></name></person-group><article-title>Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents</article-title><source>Biochem Pharmacol</source><volume>83</volume><year>2012</year><fpage>1172</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">22285227</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.R.</given-names></name><name><surname>Jiang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Quercetin reverses cardiac systolic dysfunction in mice fed with a high-fat diet: role of angiogenesis</article-title><source>Oxid Med Cell Longev</source><volume>2021</volume><year>2021</year><fpage>8875729</fpage><pub-id pub-id-type="pmid">33688395</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Casta&#x000f1;eda</surname><given-names>D.</given-names></name><name><surname>Gabani</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Targeting autophagy in obesity-associated heart disease</article-title><source>Obesity (Silver Spring)</source><volume>27</volume><year>2019</year><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">30938942</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Kubli</surname><given-names>D.A.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction</article-title><source>J&#x000a0;Biol Chem</source><volume>288</volume><year>2013</year><fpage>915</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">23152496</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Ding</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Parkin regulates programmed necrosis and myocardial ischemia/reperfusion injury by targeting cyclophilin-D</article-title><source>Antioxid Redox Signal</source><volume>31</volume><year>2019</year><fpage>1177</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">31456416</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Zhai</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy</article-title><source>Circ Res</source><volume>124</volume><year>2019</year><fpage>1360</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">30786833</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Marek-Iannucci</surname><given-names>S.</given-names></name><name><surname>Tucker</surname><given-names>K.C.</given-names></name><name><surname>Andres</surname><given-names>A.M.</given-names></name><name><surname>Gottlieb</surname><given-names>R.A.</given-names></name></person-group><article-title>Decrease of cardiac Parkin protein in obese mice</article-title><source>Front Cardiovasc Med</source><volume>6</volume><year>2019</year><fpage>191</fpage><pub-id pub-id-type="pmid">32039238</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><etal/></person-group><article-title>FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity</article-title><source>Sci Adv</source><volume>6</volume><year>2020</year><object-id pub-id-type="publisher-id">eabc8561</object-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.Y.</given-names></name><name><surname>Stevens</surname><given-names>M.V.</given-names></name><name><surname>Akter</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells</article-title><source>J&#x000a0;Clin Invest</source><volume>121</volume><year>2011</year><fpage>3701</fpage><lpage>3712</lpage><pub-id pub-id-type="pmid">21865652</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Santulli</surname><given-names>G.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Reiken</surname><given-names>S.R.</given-names></name><name><surname>Marks</surname><given-names>A.R.</given-names></name></person-group><article-title>Mitochondrial calcium overload is a key determinant in heart failure</article-title><source>Proc Natl Acad Sci U S A</source><volume>112</volume><year>2015</year><fpage>11389</fpage><lpage>11394</lpage><pub-id pub-id-type="pmid">26217001</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Deficiency of PKD2L1 (TRPP3) exacerbates pathological cardiac hypertrophy by augmenting NCX1-mediated mitochondrial calcium overload</article-title><source>Cell Rep</source><volume>24</volume><year>2018</year><fpage>1639</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">30089272</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Overexpression of SERCA2a alleviates cardiac microvascular ischemic injury by suppressing Mfn2-mediated ER/mitochondrial calcium tethering</article-title><source>Front Cell Dev Biol</source><volume>9</volume><year>2021</year><fpage>636553</fpage><pub-id pub-id-type="pmid">33869181</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PINK1 contained in huMSC-derived exosomes prevents cardiomyocyte mitochondrial calcium overload in sepsis via recovery of mitochondrial Ca<sup>2+</sup> efflux</article-title><source>Stem Cell Res Ther</source><volume>12</volume><year>2021</year><fpage>269</fpage><pub-id pub-id-type="pmid">33957982</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.W.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Semple</surname><given-names>I.A.</given-names></name><etal/></person-group><article-title>Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers</article-title><source>Nat Commun</source><volume>5</volume><year>2014</year><fpage>4834</fpage><pub-id pub-id-type="pmid">25189398</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Kusminski</surname><given-names>C.M.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>R.</given-names></name><etal/></person-group><article-title>MitoNEET-Parkin effects in pancreatic alpha- and beta-cells, cellular survival, and intrainsular cross talk</article-title><source>Diabetes</source><volume>65</volume><year>2016</year><fpage>1534</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">26895793</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Matteucci</surname><given-names>A.</given-names></name><name><surname>Patron</surname><given-names>M.</given-names></name><name><surname>Vecellio Reane</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Parkin-dependent regulation of the MCU complex component MICU1</article-title><source>Sci Rep</source><volume>8</volume><year>2018</year><fpage>14199</fpage><pub-id pub-id-type="pmid">30242232</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis</article-title><source>J&#x000a0;Pineal Res</source><volume>63</volume><year>2017</year><fpage>e12413</fpage></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Madungwe</surname><given-names>N.B.</given-names></name><name><surname>Imam Aliagan</surname><given-names>A.D.</given-names></name><name><surname>Tombo</surname><given-names>N.</given-names></name><name><surname>Bopassa</surname><given-names>J.C.</given-names></name></person-group><article-title>Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels</article-title><source>Biochem Biophys Res Commun</source><volume>520</volume><year>2019</year><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">31623831</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>S.</given-names></name><name><surname>Holmstrom</surname><given-names>K.M.</given-names></name><name><surname>Skujat</surname><given-names>D.</given-names></name><etal/></person-group><article-title>PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1</article-title><source>Nat Cell Biol</source><volume>12</volume><year>2010</year><fpage>119</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">20098416</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Fung</surname><given-names>G.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>NBR1 is dispensable for PARK2-mediated mitophagy regardless of the presence or absence of SQSTM1</article-title><source>Cell Death Dis</source><volume>6</volume><year>2015</year><object-id pub-id-type="publisher-id">e1943</object-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Burslem</surname><given-names>G.M.</given-names></name><name><surname>Crews</surname><given-names>C.M.</given-names></name></person-group><article-title>Proteolysis-targeting chimeras as therapeutics and tools for biological discovery</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">31955850</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Appendix</title><p id="p0240">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplemental Methods</title></caption><media xlink:href="mmc1.docx"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0235">Human samples were provided by Dr Jun Tao from Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Ribonucleic acid sequencing data of human heart samples was provided by Dr Marcin Wozniak from the University of Leicester.</p></ack><fn-group><fn id="d35e739"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors&#x02019; institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <ext-link ext-link-type="uri" xlink:href="https://www.jacc.org/author-center" id="interref1">Author Center</ext-link>.</p></fn><fn id="appsec2"><p>Appendix</p><p id="p0245">For a supplemental Methods section, tables, and references, please see the online version of this paper.</p></fn></fn-group></back></article>
